The omics revolution

  • In the field of Big Data, after genomics and proteomics, appeared metabolomics and lipidomics, i.e. the study of all the molecules linked to the metabolism and lipid composition of organs and plasma.
  • Numerous studies have shown that this molecular signature changes during the course of cardiometabolic diseases, and that it can be used as a biomarker or therapeutic target.. An example is the link between serum lipid profile and the risk of progression of atherosclerosis.
  • Gender, body mass index, age, lifestyle… Many factors modify this metabolic and lipid signature, making it difficult to study.

The ICAN Omics scientific platform

With its scientific platforms ICAN Omics lipidomics et metabolomics, the IHU ICAN develops innovative, holistic approaches targeting a broad spectrum of molecules, from highly polar metabolites to highly apolar lipids thanks to the combination of chromatography (liquid (LC) or gas (GC)) coupled with mass spectrometry technology (HRMS, MS/MS ou MS).

Various tools have been developed for data integration and analysis, including a dedicated multi-omics integration method for discriminating metabolic phenotypes (called DIABLO).

Following a new audit at the end of 2023, the ICAN Omics platform was awarded the renewal of the IBiSA label, which attests to the quality of the activity of platforms and Biological Resource Centers (BRCs) of regional or national interest in biology, health and agronomy.

ICAN Omics lipidomics

The ICAN Omics lipidomics platform lipidomicsidentified new lipid biomarkers in cardiometabolism and nutrition, with the aim of improving prevention and refining patient stratification for more personalized treatment.

ICAN Omics metabolomics

The ICAN Omics metabolomics platform aims to develop and supply tools for high-throughput profiling and/or quantification of all molecules belonging to the metabolome, for mechanistic purposes or in the search for new biomarkers.